Tyrer-Cuzick Breast Cancer Risk Score
The Tyrer-Cuzick (TC) model is a validated statistical risk assessment tool that calculates both 10-year and lifetime breast cancer risk by incorporating family history, personal risk factors (age, reproductive history, breast density, hormonal factors), and can integrate genetic information—with a lifetime risk ≥20% defining high-risk status that triggers recommendations for supplemental MRI screening and consideration of risk-reduction strategies 1.
How the TC Score is Calculated
The TC model integrates multiple risk factors into a comprehensive algorithm:
Core Input Variables
- Family history: Number and type of relatives with breast/ovarian cancer, their ages at diagnosis, and lineage (maternal vs paternal)
- Personal factors: Current age, age at menarche, age at first live birth, parity, menopausal status, age at menopause
- Breast characteristics: Mammographic density (critical component that significantly impacts risk)
- Hormonal exposures: Hormone replacement therapy use and duration
- Genetic information: Can incorporate known pathogenic variants or polygenic risk scores when available 2
The model generates both a 10-year absolute risk percentage and a lifetime risk percentage (typically calculated to age 80-85).
Risk Category Interpretation
Risk Stratification Thresholds
According to ACR guidelines 1:
- Average risk: <15% lifetime risk
- Intermediate risk: 15-20% lifetime risk
- High risk: >20% lifetime risk
The critical 20% lifetime risk threshold determines eligibility for enhanced screening with annual breast MRI starting as early as age 25-30, in addition to mammography 3.
Clinical Decision Points
For 10-year risk assessment:
- A 10-year risk ≥1.66-1.7% may qualify women for chemoprevention discussions with tamoxifen or raloxifene 4
- This threshold is particularly relevant for women aged 35-50 when considering risk-reduction medications
Performance Characteristics and Limitations
Accuracy in General Populations
The TC model demonstrates good calibration in screening populations. In a large validation study of 132,139 women followed for up to 19 years, the observed-to-expected ratio was 0.98 (95% CI 0.94-1.02) when density was included, with hazard ratios of 2.55 for the highest risk decile 5. Importantly, the model maintained accuracy throughout the entire 10-year follow-up period without significant degradation 5.
Critical Caveats
The TC model has significant limitations in specific high-risk populations:
Lobular carcinoma in situ (LCIS): The model substantially overpredicts risk in women with LCIS (C-index 0.493), making it unreliable for this population 6. Do not use TC for risk assessment in LCIS patients.
Model discordance: When compared to other risk models (Gail, BRCAPRO), only 0.2% of women are classified as high-risk by all three models simultaneously 7. The TC model identifies significantly more high-risk women than the Gail model (odds ratio 6.4-7.4) 7.
Practical Implementation
When to Perform Risk Assessment
All women should undergo breast cancer risk assessment by age 25-30, particularly Black women and those of Ashkenazi Jewish descent who have higher rates of actionable mutations 3.
Key Risk Factors That Drive TC Scores
Research identifies three independent factors with the greatest impact on lifetime risk 8:
- Mammographic breast density (category C or D)
- First-degree relatives with breast cancer
- Age at first birth >30 years
These factors serve as clinical triggers to pursue formal TC calculation and potential high-risk referrals 8.
Real-World Utilization Patterns
In screening populations, approximately 7.7-13.7% of women are identified as high-risk by TC 9, 10. However, only 51-75% of identified high-risk women complete recommended supplemental MRI screening, and uptake of risk-reducing medications remains very low (7.6%) 10.
Clinical Actions Based on TC Results
For High-Risk Women (≥20% lifetime risk):
- Annual screening breast MRI starting age 25-30 (depending on risk type)
- Annual mammography with variable start age 25-40 based on specific risk factors 1
- Consider genetic counseling if not already completed
- Discuss chemoprevention options (tamoxifen, raloxifene, aromatase inhibitors for postmenopausal women)
For Intermediate-Risk Women (15-20% lifetime risk):
- Enhanced surveillance strategies should be considered
- Individual discussion about supplemental screening modalities
- Particularly important if additional risk factors present (dense breasts, personal history of atypia)
Documentation and Follow-up
TC scores should be recalculated periodically as risk factors change (new family history, changes in breast density, advancing age). The model provides useful long-term prediction for at least 10 years 5, 11.